Kindred Hospital Rehabilitation Services Expands Pilot of Ekso Bionics®’ EksoGT Exoskeleton to Enhance Stroke Rehabilitati...
May 03 2019 - 08:00AM
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced that Kindred Hospital Rehabilitation Services
("Kindred"), a division of Kindred Healthcare, has expanded their
pilot of the EksoGT exoskeleton to offer advanced stroke
rehabilitation at the majority of their sites - over 20
freestanding inpatient Kindred rehabilitation hospitals in 13
states.
The pilot began over a year ago and has since
been expanded to the majority of their sites, making Kindred Ekso
Bionics’ largest partner offering EksoGT at the most locations
within a single network. Kindred aims to improve patient outcomes
with the EksoGT by mobilizing patients earlier, more frequently,
and with a greater number of high intensity steps during their
rehab sessions.
“It is our mission to provide greater access to
advanced rehabilitation, and we are excited to incorporate the
EksoGT into our offering at most of our inpatient rehabilitation
hospitals,” said Russ Bailey, COO/Senior Vice President of
Operations at Kindred. “We believe having access to leading
technology can improve patient outcomes, as well as increase their
morale during the process. A win-win for our patients.”
EksoGT is the most widely used exoskeleton
device in rehabilitation, designed to help patients get back on
their feet by supporting re-learning of correct step patterns,
weight shifting, and potentially mitigating compensatory behaviors,
enabling patients to mobilize earlier and restore independence. It
is the only exoskeleton with SmartAssist software which provide
adaptive amounts of power to either side of a patient’s body,
especially beneficial for stroke patients.
“Innovative customers like Kindred are in a
position to advance stroke rehabilitation by equipping their
clinicians with EksoGT,” said Jack Peurach, CEO and President of
Ekso Bionics. “With locations throughout the country, Kindred is
able to improve more patients’ lives and is leading the way in
changing the standard of care.”
To find a Kindred location with EksoGT near you, visit
www.eksobionics.com/centers or www.kindredhealthcare.com.
About Kindred HealthcareKindred
Hospital Rehabilitation Services is part of Kindred Healthcare,
LLC, a healthcare services company based in Louisville,
Kentucky with annual revenues of approximately $3.3
billion. At December 31, 2018, Kindred through its subsidiaries had
approximately 35,700 employees providing healthcare services in
1,789 locations in 45 states, including 74 long-term acute care
hospitals, 22 inpatient rehabilitation hospitals, 11 sub-acute
units, 96 inpatient rehabilitation units (hospital-based) and
contract rehabilitation service businesses which served 1,586
non-affiliated sites of service. Ranked as one of Fortune
Magazine's Most Admired Healthcare Companies for nine years,
Kindred's mission is to help our patients reach their highest
potential for health and healing with intensive medical and
rehabilitative care through a compassionate patient experience. For
more information, go to www.kindredhealthcare.com. You can
also follow us on Twitter and Facebook.
About EksoGTEksoGT is the first
exoskeleton cleared by the FDA for use with stroke and spinal cord
injuries from L5 to C7. In Europe, the CE-Mark cleared EksoGT
allows us to work with patients impacted by all neurological
conditions and lower limb weakness. The EksoGT with SmartAssist
software is the only exoskeleton available for rehabilitation
institutions that can provide adaptive amounts of power to either
side of a patient’s body, challenging the patient as they progress
through their continuum of care. The suit’s patented technology
provides the ability to mobilize patients earlier, more frequently,
and with a greater number of high intensity steps. To date, this
device has helped patients take 100 million steps in over 260
rehabilitation institutions around the world.
About Ekso Bionics® Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. The company is
headquartered in the Bay Area and is listed on the Nasdaq Capital
Market under the symbol EKSO. For more information,
visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:Glenn
Silver646-871-8485eksobionics@lazarpartners.com
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2023 to Mar 2024